BC
WST icon

Barrett & Company’s West Pharmaceutical WST Stock Holding History

Barrett & Company’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.6K Sell
74
-75
-50% -$22.9K 0.01% 385
2026
Q1 		$37.3K Hold
149
– – 0.01% 325
2025
Q4 		$41K Hold
149
– – 0.01% 320
2025
Q3 		$39.1K Hold
149
– – 0.01% 327
2025
Q2 		$32.6K Hold
149
– – 0.01% 353
2025
Q1 		$33.4K Hold
149
– – 0.01% 315
2024
Q4 		$48.8K Sell
149
-25
-14% -$7.87K 0.02% 272
2024
Q3 		$52.2K Sell
174
-115
-40% -$35.2K 0.02% 253
2024
Q2 		$95.3K Hold
289
– – 0.04% 200
2024
Q1 		$114K Hold
289
– – 0.05% 184
2023
Q4 		$102K Hold
289
– – 0.06% 186
2023
Q3 		$109K Hold
289
– – 0.06% 170
2023
Q2 		$111K Hold
289
– – 0.06% 170
2023
Q1 		$100K Hold
289
– – 0.06% 175
2022
Q4 		$68.1K Hold
289
– – 0.05% 208
2022
Q3 		$68.1K Buy
+289
New +$88K 0.05% 208

Other funds holding WST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Barrett & Company's WST Position: Q2 2026 in Review

Barrett & Company reduced its West Pharmaceutical (WST) stake by 50% in Q2 2026, selling an estimated $22.9K and leaving 74 shares worth $26.6K. The position accounts for 0.01% of the portfolio, ranked #385.

Barrett & Company first reported a position in WST in Q3 2022 and has held it in 16 quarters since. The position peaked at $114K in Q1 2024. 832 funds tracked by Wall St. Rank hold WST as of Q2 2026.

  • Barrett & Company held 74 shares of West Pharmaceutical worth $26.6K as of Q2 2026.
  • Barrett & Company sold 75 West Pharmaceutical shares in Q2 2026, an estimated $22.9K.
  • West Pharmaceutical made up 0.01% of Barrett & Company's portfolio in Q2 2026, its #385 holding.
  • Barrett & Company first reported a position in West Pharmaceutical in Q3 2022 and has held it in 16 quarters since.
  • Barrett & Company's West Pharmaceutical position peaked at $114K in Q1 2024.
  • 832 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on Barrett & Company's 13F filing for Q2 2026, filed 24 Jul 2026.